Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2021 | $91 M | No. 4 | $50 to $250 million | equity, options | SEC | |
| Jul 2020 | $60 M | No. 3 | $50 to $250 million | equity, options | SEC | |
| Jan 2019 | $25 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Nov 2014 | $30 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
N30 Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2021).
SEC Form D · Sep 2021
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Sep 2021
That is all the official record says: N30 Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund II, L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design International II, Ltd. | Company | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design International, L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Estate of Arnold H. Snider, III | Person | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Hadley Harbor Master Investors (Cayman) L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Hawkes Bay Master Investors (Cayman) L.P. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Jennison Global Healthcare Master Fund, Ltd. | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Rock Springs Capital Management LP | Fund or asset manager | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 25 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James Paul Rickey | Senior Vice President and Chief Financial Officer | Sep 2021 |
| Mitchell Paul Gold | Executive Chairman and Chief Executive Officer | Sep 2021 |
| Stanford Paul Peng | President and Head of Research and Development | Sep 2021 |
| Zelanna Paul Goldberg | Executive officer | Sep 2021 |
| Mark James Litton | President and Chief Operating Officer | Jan 2019 |
| Mitchell James Gold | Executive Chairman and Chief Executive Officer | Jan 2019 |
| Stanford James Peng | Executive Vice President of Research and Development and Chief Medical Officer | Jan 2019 |
| Tom Sokolowski | Executive officer | Nov 2014 |
| Christopher Paul Peetz | Director | Sep 2021 |
| Cui Paul Xiangmin | Director | Sep 2021 |
| James Paul Topper | Director | Sep 2021 |
| Jay Paul Venkatesan | Director | Sep 2021 |
| Mitchell Paul Gold | Executive Chairman and Chief Executive Officer | Sep 2021 |
| Natasha Paul Hernday | Director | Sep 2021 |
| Peter Paul Thompson | Director | Sep 2021 |
| Robert Paul Conway | Director | Sep 2021 |
| Paul Paul Sekhri | Director | Aug 2020 |
| Christopher James Peetz | Director | Jan 2019 |
| Cui James Xiangmin | Director | Jan 2019 |
| James James Topper | Director | Jan 2019 |
| Jay James Venkatesan | Director | Jan 2019 |
| Mitchell James Gold | Executive Chairman and Chief Executive Officer | Jan 2019 |
| Paul James Sekhri | Director | Jan 2019 |
| Peter James Thompson | Director | Jan 2019 |
| Robert James Conway | Director | Jan 2019 |
| Evan Loh | Director | Nov 2014 |
| Howard Furst | Director | Nov 2014 |
| John Moore | Director | Nov 2014 |
| Jonathan Leff | Director | Nov 2014 |
| Joseph Loscalzo | Director | Nov 2014 |